Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 267

1.

Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma.

Hilvering B, Hinks TSC, Stöger L, Marchi E, Salimi M, Shrimanker R, Liu W, Chen W, Luo J, Go S, Powell T, Cane J, Thulborn S, Kurioka A, Leng T, Matthews J, Connolly C, Borg C, Bafadhel M, Willberg CB, Ramasamy A, Djukanović R, Ogg G, Pavord ID, Klenerman P, Xue L.

Mucosal Immunol. 2018 Jun 15. doi: 10.1038/s41385-018-0049-9. [Epub ahead of print]

PMID:
29907870
2.

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.

Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A.

N Engl J Med. 2018 May 21. doi: 10.1056/NEJMoa1804092. [Epub ahead of print]

3.

Biologics and chronic obstructive pulmonary disease.

Pavord ID.

J Allergy Clin Immunol. 2018 Jun;141(6):1983-1991. doi: 10.1016/j.jaci.2018.04.020. Epub 2018 May 4.

PMID:
29729941
4.

Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma.

Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, Pavord ID, Zhang B, Staudinger H, Pirozzi G, Amin N, Akinlade B, Eckert L, Chao J, Graham NMH, Teper A.

Adv Ther. 2018 May 3. doi: 10.1007/s12325-018-0702-4. [Epub ahead of print]

5.

Blood eosinophil levels as a biomarker in COPD.

Brusselle G, Pavord ID, Landis S, Pascoe S, Lettis S, Morjaria N, Barnes N, Hilton E.

Respir Med. 2018 May;138:21-31. doi: 10.1016/j.rmed.2018.03.016. Epub 2018 Mar 15. Review.

PMID:
29724389
6.

Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles.

Ghebre MA, Pang PH, Diver S, Desai D, Bafadhel M, Haldar K, Kebadze T, Cohen S, Newbold P, Rapley L, Woods J, Rugman P, Pavord ID, Johnston SL, Barer M, May RD, Brightling CE.

J Allergy Clin Immunol. 2018 Jun;141(6):2027-2036.e12. doi: 10.1016/j.jaci.2018.04.013. Epub 2018 Apr 28.

7.

Associations between blood eosinophils and decline in lung function among adults with and without asthma.

Hancox RJ, Pavord ID, Sears MR.

Eur Respir J. 2018 Apr 19;51(4). pii: 1702536. doi: 10.1183/13993003.02536-2017. Print 2018 Apr.

PMID:
29563173
8.

Mepolizumab for Eosinophilic COPD.

Sciurba FC, Bradford ES, Pavord ID.

N Engl J Med. 2018 Feb 15;378(7):681-683. doi: 10.1056/NEJMc1715454. No abstract available.

9.

COUNTERPOINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30% ≤ FEV1 < 50% Predicted) COPD? No.

Pavord ID.

Chest. 2018 Apr;153(4):782-784. doi: 10.1016/j.chest.2018.01.030. Epub 2018 Feb 2. No abstract available.

PMID:
29410364
10.

Rebuttal From Dr Pavord.

Pavord ID.

Chest. 2018 Apr;153(4):786-787. doi: 10.1016/j.chest.2018.01.026. Epub 2018 Feb 2. No abstract available.

PMID:
29410251
11.

'We can't diagnose asthma until '.

Bush A, Pavord ID.

Arch Dis Child. 2018 Jan 5. pii: archdischild-2017-314180. doi: 10.1136/archdischild-2017-314180. [Epub ahead of print] No abstract available.

PMID:
29305357
12.

A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial.

Hanratty CE, Matthews JG, Arron JR, Choy DF, Pavord ID, Bradding P, Brightling CE, Chaudhuri R, Cowan DC, Djukanovic R, Gallagher N, Fowler SJ, Hardman TC, Harrison T, Holweg CT, Howarth PH, Lordan J, Mansur AH, Menzies-Gow A, Mosesova S, Niven RM, Robinson DS, Shaw DE, Walker S, Woodcock A, Heaney LG; RASP-UK (Refractory Asthma Stratification Programme) Consortium.

Trials. 2018 Jan 4;19(1):5. doi: 10.1186/s13063-017-2384-7.

13.

Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma.

Gunsoy NB, Cockle SM, Yancey SW, Keene ON, Bradford ES, Albers FC, Pavord ID.

J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):874-882.e4. doi: 10.1016/j.jaip.2017.11.026. Epub 2017 Dec 16.

14.

Physiotherapy breathing retraining for asthma: a randomised controlled trial.

Bruton A, Lee A, Yardley L, Raftery J, Arden-Close E, Kirby S, Zhu S, Thiruvothiyur M, Webley F, Taylor L, Gibson D, Yao G, Stafford-Watson M, Versnel J, Moore M, George S, Little P, Djukanovic R, Price D, Pavord ID, Holgate ST, Thomas M.

Lancet Respir Med. 2018 Jan;6(1):19-28. doi: 10.1016/S2213-2600(17)30474-5. Epub 2017 Dec 14.

15.

Author Correction: The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β2-agonists in the United Kingdom: a cross-sectional analysis.

Pavord ID, Mathieson N, Scowcroft A, Pedersini R, Isherwood G, Price D.

NPJ Prim Care Respir Med. 2017 Dec 5;27(1):65. doi: 10.1038/s41533-017-0063-5.

16.

Cytometric Gating Stringency Impacts Studies of Type 2 Innate Lymphoid Cells in Asthma.

Hinks TSC, Batty P, Klenerman P, Pavord ID, Xue L.

Am J Respir Cell Mol Biol. 2017 Dec;57(6):745-747. doi: 10.1165/rcmb.2017-0201LE. No abstract available.

17.

The Significance of Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease.

Cooper CB, Brusselle G, Pascoe SJ, Pavord ID.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):967-968. doi: 10.1164/rccm.201709-1797LE. No abstract available.

PMID:
29140724
18.

Treating asthma exacerbations in athletes: TUE or not TUE?

Hull JH, Pavord ID.

Lancet Respir Med. 2018 Jan;6(1):8-10. doi: 10.1016/S2213-2600(17)30428-9. Epub 2017 Oct 30. No abstract available.

PMID:
29097025
19.

Precision medicine in airway diseases: moving to clinical practice.

Agustí A, Bafadhel M, Beasley R, Bel EH, Faner R, Gibson PG, Louis R, McDonald VM, Sterk PJ, Thomas M, Vogelmeier C, Pavord ID; on behalf of all participants in the seminar.

Eur Respir J. 2017 Oct 19;50(4). pii: 1701655. doi: 10.1183/13993003.01655-2017. Print 2017 Oct.

PMID:
29051276
20.

After asthma: redefining airways diseases.

Pavord ID, Beasley R, Agusti A, Anderson GP, Bel E, Brusselle G, Cullinan P, Custovic A, Ducharme FM, Fahy JV, Frey U, Gibson P, Heaney LG, Holt PG, Humbert M, Lloyd CM, Marks G, Martinez FD, Sly PD, von Mutius E, Wenzel S, Zar HJ, Bush A.

Lancet. 2018 Jan 27;391(10118):350-400. doi: 10.1016/S0140-6736(17)30879-6. Epub 2017 Sep 11. Review. No abstract available.

Supplemental Content

Loading ...
Support Center